Welcome!   Login
Supported by the Agency for Healthcare Research and Quality (AHRQ) and co-sponsored by the International Society of Geriatric Oncology (SIOG), the American Geriatrics Society (AGS), and the GSA Informal Interest Group Research on Cancer and Aging.

This series will include 3 sessions on topics related to comparative effectiveness research in older cancer patients. It is designed to create new opportunities for a broader national audience to discuss and provide suggestions of areas and questions that require comparative effectiveness evaluation in order to help both the provider and the older cancer patient. In this context, health status refers to functional status, comorbid conditions, and other factors common among older adults that may affect life expectancy independent of advanced age itself. As suggested in its name, at the heart of comparative effectiveness research is the ability to "compare," but in most cancer research involving older adults, it has been difficult to distinguish differences in effectiveness related to health status versus differences related to aging.
Seminar Information
Seminar Date:
November 19, 2010
Seminar Location:
Hilton New Orleans Riverside
New Orleans, LA
Click on a topic name to see details and purchase options.
Friday November 19, 2010
 Objectives:
  1. Highlight different considerations between younger and older individuals as it pertains to colon, prostate, and breast cancer screening.
  2. Discuss the role of functional status and comorbidity with respect to the value of colon, prostate, and breast cancer screening.
  3. Define important unanswered questions that would benefit from comparative effectives with respect to colon, prostate, and breast cancer screening.
Speaker Information
Erica S. Breslau PhD, MPH
William Dale MD, PhD
Arash Naeim MD, PhD
Janine Overcash PhD, GNP-BC
Saturday November 20, 2010
Objectives:
  1. Highlight different considerations between younger and older individuals as it pertains to breast, colon, and lung cancer adjuvant therapy.
  2. Discuss the role of functional status and comorbidity with respect to the value of breast, colon, and lung cancer adjuvant therapy.
  3. Define important unanswered questions that would benefit from comparative effectives with respect to breast, colon, and lung cancer adjuvant therapy.
Speaker Information
Arti Hurria MD
Arash Naeim MD, PhD
Sunday November 21, 2010
  1. Highlight different considerations between younger and older individuals as it pertains to functional decline, psychosocial issues, and the role of caregivers in cancer survivors.
  2. Discuss the role of functional status and comorbidity as it pertains to functional decline, psychosocial issues, and the role of caregivers in cancer survivors.
  3. Define important unanswered questions that would benefit from comparative effectives with respect to functional decline, psychosocial issues, and the role of caregivers in cancer survivors
Speaker Information
Charles W. Given PhD
Arash Naeim MD, PhD
Julia Hannum Rose PhD
Individual topic purchase: Selected
Products
Streaming
This seminar is presented free of charge.